Clobetasol
Names
[ CAS No. ]:
25122-41-2
[ Name ]:
Clobetasol
[Synonym ]:
(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
UNII-ADN79D536H
Clobetasolum
EINECS 246-633-8
Clobetasol [INN:BAN]
21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
Clobetasolum [INN-Latin]
Chemical & Physical Properties
[ Density]:
1.32 g/cm3
[ Boiling Point ]:
555.1ºC at 760 mmHg
[ Melting Point ]:
195 - 197C (decomposes)ºC
[ Molecular Formula ]:
C22H28ClFO4
[ Molecular Weight ]:
410.90700
[ Flash Point ]:
289.5ºC
[ Exact Mass ]:
410.16600
[ PSA ]:
74.60000
[ LogP ]:
3.14220
[ Vapour Pressure ]:
1.23E-14mmHg at 25°C
[ Index of Refraction ]:
1.582
[ Storage condition ]:
-20?C Freezer
Safety Information
[ Symbol ]:
GHS08
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H360Df-H373-H413
[ Precautionary Statements ]:
P201-P308 + P313
[ Target Organs ]:
Adrenal gland, Immune system
[ Hazard Codes ]:
T
[ Risk Phrases ]:
61-48/20/21-53-62
[ Safety Phrases ]:
53-36/37-45
[ RIDADR ]:
NONH for all modes of transport
Articles
Ann. R. Coll. Surg. Engl. 95(4) , 291-6, (2013)
Chronic, non-healing wounds are often characterised by an excessive, and detrimental, inflammatory response. We review our experience of using a combined topical steroid, antibiotic and antifungal pre...
Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.Journal. of. Drugs in. Dermatology. 11(11) , 1348-54, (2012)
Psoriasis causes significant distress and impairment in health-related quality of life (QOL) in afflicted patients. For this reason, QOL is an essential and important measure of treatment outcome in p...
Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.Cutis. 89(2) , 89-94, (2012)
Clobetasol propionate is a super-high potent class 1 topical corticosteroid available in several formulations, including a spray formulation that is approved for use up to 4 weeks in patients aged 18 ...